Business Wire

Tecnotree Reports Consistent Revenue, Margin Expansion and Three Consecutive Quarters Of Positive Free Cashflow

26.2.2025 10:49:00 CET | Business Wire | Press release

Share

Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced its financial results for the fourth quarter and full year of 2024. 2024 was a pivotal year for Tecnotree despite macro economic challenges, the company delivered 3 consecutive quarters of positive free cash flow achieving and strong ARR growth by 8% YoY from 2023. Further the company delivered on the guidance previously announced achieving a revenue increase of 4% YoY in constant currency, an increase of EBIT of 9% YoY in constant currency and an increase in Free Cash Flow by 7.9 Million Euro in 2024 from the previous period. In 2024, the company’s strategic cost optimization achieved higher savings than previously committed. Tecnotree had taken precautionary measures and made adequate provisions to exit markets which are characterised with geo-political risks, areas of conflict or regions with high risks of sanctions. Further, Tecnotree achieved a breakthrough Tier 1 telco deal in the United States, in collaboration with a leading Systems Integrator (SI) as previously announced, validating our investment in TM Forum Standards and our ability to secure recurring revenue streams in Dollar denominated enterprise markets, paving the way for sustainable growth in the future.

Q4 Results

  • Net sales of EUR 17.6 million (22.2) -20.7% Year on Year, In constant currency,
    -16.5% Year on Year.
  • Operating profit of EUR 10.9 million (7.9) +38.1% Year on Year.
  • Operating margin of 61.7% (35.4%).
  • Foreign exchange losses reduced EUR 0.3 million (6.0).
  • Net income for the quarter was EUR 0.5 million (2.4) -79% Year on Year.
  • Adjusted net income for quarter EUR 4.9 million (2.4) +104% Year on Year.
  • Gross cash inflow from operating activities EUR 8.4 million (9.9).
  • Positive free cash flow of EUR 0.4 million (-0.6), the third quarter in a row.
  • Earnings per share EUR 0.03 (0.01*).
  • Order book at the end of the period EUR 79.6 million (80.2).

Full year Results

  • Net sales of EUR 71.6 million (78.4) –8.6% Year on Year, in constant currency +4.0% Year on Year, in line with guidance.
  • Operating profit EUR 23.8 million (23.8) flat Year on Year, however operating profit margin expanded to 33.2% (30.4%). Operating profit in constant currency EUR 26.0 million, +9.0 % Year on Year in line with guidance.
  • Foreign exchange losses reduced to EUR 2.5 million (9.7).
  • Net Income for the period EUR 8.3 million (11.2) -25.8% Year on Year due to one-time items pertaining to EUR 7.3 million.
  • Adjusted net income was EUR 15.6 million (11.2) +39.3% Year on Year.
  • Gross cash inflow from operating activities EUR 21.3 million (17.4).
  • Free cash flow stands at EUR -1.8 million ( -9.7).
  • Free cash flow for H2 stands at EUR 2.2 million (-3.9) in line with guidance.
  • Earnings per share were EUR 0.5 (0.04*).

"Tecnotree’s SISU-driven execution has delivered a pivotal year of transformation, resilience, and growth. With three consecutive quarters of positive free cash flow, a landmark Tier 1 telco deal in the U.S., and a strengthened focus on AI-powered automation, we have reinforced our financial position and market leadership. Our cost optimization initiatives exceeded expectations, while our ARR expansion and strategic shift to Tier 1 and dollar-denominated markets ensure a scalable and profitable future. As we step into 2025, we remain committed to driving AI-led innovation, sustainable growth, and delivering long-term value to our investors and customers."

Padma Ravichander, CEO, Tecnotree

Significant milestones and business achievements for the year included:

  • Tecnotree Increased productivity from AI/ML consistently executing 5-7 digital transformations per quarter, reinforcing our ability to scale revenue with efficiency.
  • 2024 Gartner® Magic Quadrant for AI in CSPs – A first-time recognition for our AI-driven telco transformations.
  • Among the Top 2 Global Telecom Revenue Management Providers (Precision Reports, for the 2nd consecutive year.
  • Featured in 4 Gartner® HypeCycles & 2 Gartner® Market Guides for CSP digital marketplaces, revenue management, and Customer Management solutions.
  • Named one of the fastest-growing BSS providers by Omdia in 2024, highlighting our momentum against legacy competitors.
  • In 2024 Tecnotree for the second consecutive year was recognized as a top-performing company in the Nordic Business Diversity Index (Mid-Cap Segment), reinforcing our commitment to building inclusive, digitally connected communities while delivering strong financial outcomes.

About Tecnotree

Tecnotree is a 5G-ready digital Business Support System (BSS) player, with AI/ML capabilities and multi-cloud extensibility. Tecnotree leads the way on the TM Forum Open API Conformance with 59 certified Open APIs including 9 real-world open APIs, a testament to the company's commitment to excellence, and continuously striving to deliver differentiated experiences and services to both CSPs and DSPs. Our agile and open-source digital BSS Stack comprises the full range (order-to-cash) of business processes and subscription management for telecom and other digital services industries creating opportunities beyond connectivity. Tecnotree also provides Fintech and B2B2X multi-experience digital marketplace to its subscriber base through the Tecnotree Moments platform to empower digitally connected communities across gaming, health, education, OTT, and other vertical ecosystems. Tecnotree is listed on the Helsinki Nasdaq (TEM1V).

View source version on businesswire.com: https://www.businesswire.com/news/home/20250226249918/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye